OKEP Oct'15

1.

Name:

2.

Territory:

3.

Email Id:

4.

SGAs have been replacing FGAs as the first drug of choice in the treatment of ____?

(a) Parkinson

(b) Alzheimer

(c) Schizophrenia.

(d) Epilepsy

5.

Which two strategies are commonly used when switching antipsychotics?

(a) Abrupt & cross tapering

(b) Gradual & simple tapering

(c) Gentle and deliberate tapering

(d) None

6.

Which of the following SGA’s is with the lowest mean body weight gain and less effect on risk for adverse metabolic changes?

(a) Chlorpromazine

(b) Perphenazine

(c) Aripiprazole

(d) Fluphenazine

7.

Aripiprazole is a novel antipsychotic agent with unique mechanisms of partial agonism at ____?

(a) dopamine D2 receptors and serotonin 5- HT1A receptors

(b) dopamine D1 receptors and serotonin 5- HT1A receptors

(c) dopamine D2 receptors and serotonin 5- HT2A receptors

(d) dopamine D1 receptors and serotonin 5- HT1B receptors

8.

Aripiprazole efficacy and safety are well documented and it is effective in the treatment of both ___?

(a) Chronic and relapse phases of chronic schizophrenia

(b) Acute and relapse phases of chronic schizophrenia

(c) Both (a) & (b)

(d) None

9.

Which are the two main reasons for switching antipsychotics to Aripiprazole?

(a) Weight loss and metabolic syndrome

(b) Weight gain and Asperger syndrome

(c) Weight gain and Anxiety disorder

(d) weight gain and metabolic syndrome

10.

Which statistical software was applied for the data analysis?

(a) SPSS 12.0

(b) SPSS 14.0

(c) SPSS 15.0

(d) SPSS 20.0

11.

Less than ___ of the patients reported adverse effects while switching to aripiprazole?

(a) 29 %

(b) 30 %

(c) 31 %

(d) 32 %

12.

Market Value of aripiprazole (MAT JAN 15) is?

(a) INR Crs 24.3

(b) INR Crs 25.3

(c) INR Crs 26.3

(d) INR Crs 27.3